A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...
Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%. The trial results ...
Abstract: Threats that have been primarily targeting nation states and their associated entities have expanded the target zone to include the private and corporate sectors. This class of threats, well ...
Fighting Games 2XKO director says players should know the LoL fighting game "might not be good" at everything at first, but Riot will "address it" – "We're going to make mistakes" Fighting Games ...
A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor growth and slow symptom advance. File Photo by Billie Jean Shaw/UPI A new ...
A new drug combo is more effective in treating advanced prostate cancer The targeted drug niraparib added to hormone therapy slowed cancer growth and symptom progression Signs show the combo might ...
The targeted drug niraparib added to hormone therapy slowed cancer growth and symptom progression Signs show the combo might also improve survival FRIDAY, Oct. 10, 2025 (HealthDay News) — A new drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback